Abstract: An object is to provide a peptide gelling agent which gels under physiological conditions and which has a relatively short chain length, and a sustained-release gel based on it. Provided is a hydrogelling self-assembling peptide comprising one or two core peptides consisting of an amino acid sequence represented by the following formula: Xaa-Yaa-Zaa-Yaa-Xaa-Yaa-Zaa-Yaa-Xaa, wherein Xaa is independently Ile or Met, Yaa is independently Asp, Glu, Lys, or Arg, and Zaa is independently Ala or Gly, and wherein the full length of the amino acid sequence constituting said self-assembling peptide is 25 amino acids or less.

Abstract: A pharmaceutical composition may be used in administering oxygen to a subject. The pharmaceutical composition may contain a perfluorocarbon dissolving oxygen therein. Further, a pharmaceutical composition may be used in decreasing the blood carbon dioxide partial pressure of a subject, and the pharmaceutical composition may contain a perfluorocarbon. Such a composition may be suitable for administered oral administration, nasogastric administration, trans-fistula gastric administration, or administration into a large intestine.

Abstract: It has been revealed that, from a pre-onset stage of Alzheimer's disease, enhancement of phosphorylations of MARCKS and the like causes abnormal spine formation or the like, consequently developing the disease. It also has been revealed that the phosphorylations of MARCKS and the like are caused by PKC and the like, and further that b-raf is involved in phosphorylation of tau protein important for the progression of Alzheimer's disease. Thus, these proteins have been found to be target molecules useful in the diagnosis and treatment of Alzheimer's disease. In addition, it has also been revealed that, in a pre-onset stage of frontotemporal lobar degeneration, b-RAF phosphorylation enhancement causes a decrease in the number of spines and the like, consequently developing the disease. Thus, b-RAF has been found to be a target molecule useful in the diagnosis and treatment of frontotemporal lobar degeneration.

Abstract: The present invention provides an antisense nucleic acid medicine that can modulate expression of a target transcriptional product in an ischemic site of a subject. The present invention also provides a composition for modulating expression of a target transcriptional product in an ischemic site of a subject, having a nucleic acid complex formed by annealing together a first nucleic acid strand having an antisense oligonucleotide region with respect to the target transcriptional product, and a lipid-conjugated second nucleic acid strand having a complementary region that is complementary to at least part of the first nucleic acid strand.

Abstract: A double-stranded nucleic acid complex that can have an excellent activity is provided. In one embodiment, the present invention relates to a double-stranded nucleic acid complex having a first nucleic acid strand and a second nucleic acid strand. The first nucleic acid strand is capable of hybridizing to at least part of a target gene or a transcription thereof, has an antisense effect on the target gene or transcription product thereof, and has at least two morpholino nucleic acids The second nucleic acid strand has a base sequence complementary to the first nucleic acid strand. The first nucleic acid strand is annealed to the second nucleic acid strand.

Abstract: An objective of the present invention is to provide a biomagnetism measurement device capable of three-dimensionally acquiring magnetism information of a living body with ease. This biomagnetism measurement device (101) is for measuring biomagnetism using a plurality of magnetic sensors (1) at the same time. The plurality of magnetic sensors (1) is retained by a retaining part (10) (a first retaining portion [11] and a second retaining portion [12]) so as to have different measurement directions. Furthermore, the retaining part (10) (the first retaining portion [11] and the second retaining portion [12]) has arranged thereon the plurality of magnetic sensors (1) so as to enable biomagnetism to be measured at a plurality of sites at the same time. The magnetic sensor (1) comprises a means for detecting the biomagnetism in a temperature environment commensurate with normal temperature.

Abstract: A nerve stimulating apparatus includes a plurality of stimulating units configured to respectively apply stimuli to a plurality of nerve regions branching from a particular nerve region of a living body, and a stimulation timing controller configured to set generating timings of respectively generating the stimuli at the plurality of stimulating units. The stimulation timing controller sets the generating timings of generating the stimuli at the plurality of stimulating units based on response results of the particular nerve region, the response results being obtained in response to the stimuli that are respectively generated at the plurality of stimulating units and that are respectively applied to the plurality of nerve regions, and the response results being measured by a biometric information measuring apparatus that measures biometric information.

Abstract: The objective of the present invention is to provide a biomagnetism measuring device with which it is possible for a magnetic sensor to be disposed in an optimal position in accordance with an object being measured. A biomagnetism measuring device (1) according to the present invention is provided with: a plurality of magnetic sensors (11) which detect biomagnetism; and a holding portion (12) in which are formed frames (13) which detachably hold the plurality of magnetic sensors (11) in such a way as to face a living body. Further, the biomagnetism measuring device (1) according to the present invention is provided with: a plurality of magnetic sensors (11) which detect biomagnetism; and a holding portion (12) in which are formed rails (16) which movably hold the plurality of magnetic sensors (11) in such a way as to face a living body.

Abstract: An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, by which proliferation efficiency is improved so that a sufficient amount of synovium-derived mesenchymal stem cells can be obtained from a synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which is a method of producing a synovium-derived mesenchymal stem cell from a synovial tissue, where the production method includes treating the synovial tissue with a mixed enzyme including one or more kinds of collagenases and one or more kinds of neutral proteases for 2 hours or more without causing the synovial tissue to undergo a disinfection step.

Abstract: An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, which makes it possible to obtain a sufficient amount of synovium-derived mesenchymal stem cells from the synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which includes treating a synovial tissue with an enzyme for 2 hours or more; and washing a mixture after the enzyme treatment until a residual enzyme concentration in a supernatant is 0.5 ng/mL or less, to obtain a synovium-derived mesenchymal stem cell.

Abstract: In order to provide a device with variable rigidity and a surgical gripping device that make it possible to increase the range of change in rigidity by means of a simple structure, this device with variable rigidity is configured so as to comprise two flexible sheets (12, 14) that include: a base material (20) formed using a sheet-like elastic material and having a plurality of recesses (20B) and a plurality of protrusions (20A) formed on one surface thereof; a low rigidity section (22) that is formed using an elastic material with a lower modulus of elasticity than the base material (20) and that is arranged in the recesses (20B) and joined to the recesses (20B) so that one surface of said low rigidity section (22) becomes flat; and a friction material (24) provided to the one surface.

Abstract: It has been revealed that, from a pre-onset stage of Alzheimer's disease, enhancement of phosphorylations of MARCKS and the like causes abnormal spine formation or the like, consequently developing the disease. Moreover, it has also been revealed that the phosphorylations of MARCKS and the like are caused by PKC and the like, and further that b-raf is involved in the phosphorylation of a tau protein important for the progression of Alzheimer's disease. Thus, these proteins have been found to be target molecules useful in the diagnosis and treatment of Alzheimer's disease. In addition, it has also been revealed that, pre-onset in a stage of frontotemporal lobar degeneration also, b-RAF phosphorylation enhancement causes a decrease in the number of spines and the like, consequently developing the disease. Thus, b-RAF has been found to be a target molecule useful in the diagnosis and treatment of frontotemporal lobar degeneration.

Abstract: The present invention provides a biometric information measuring device with which a diagnostic imaging result and a biomagnetism measurement result can be superimposed simply and with satisfactory accuracy, and which is easy to handle. This biometric information measuring device (1) is provided with: a biomagnetism detecting unit (2) capable of detecting biomagnetism of a subject (S); and a radiation detecting unit (3) capable of acquiring an image corresponding to irradiated radiation, as digital image data, by means of the supply of a power source. The radiation detecting unit (3) is disposed between a measuring region of the subject (S) and the biomagnetism detecting unit (2). Further, it is preferable to provide a control unit (6) capable of performing control such that the power source is not supplied to the radiation detecting unit (3) while the biomagnetism detecting unit (2) is detecting biomagnetism.

Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

Abstract: A fluorescence image analyzer has an imaging unit for capturing a first image containing at least a part of a region of a cell as an imaging target for a plurality of cells in a sample in which a target site on a chromosome is labeled with a fluorescent dye, and a second image including fluorescence generated from a fluorescent dye labeling the target site of the cell of the first image. The processing unit selects a plurality of test cells having specific morphological characteristics to be tested from a plurality of cells based on at least the first image, and extracts the bright spots of fluorescence generated from the fluorescent dye. The processing unit identifies cells with chromosomal abnormalities and/or cells without chromosomal abnormalities based on the extracted bright spots, and generates information related to the ratio of cells with chromosomal abnormalities relative to the test cells.

Abstract: The present invention provides a composition and a method for efficiently delivering a nucleic acid agent to the central nervous system and/or the retina and bringing about antisense effects. Provided is a composition for reducing the expression level of a target transcription product in the central nervous system and/or retina of a subject, the composition including a nucleic acid complex that includes a first nucleic acid strand and a second nucleic acid strand, wherein: the first nucleic acid strand comprises a base sequence capable of hybridizing with at least part of the target transcription product and has an antisense effect on the target transcription product; the second nucleic acid strand comprises a base sequence complementary to the first nucleic acid strand and is conjugated to tocopherol, cholesterol, or an analog thereof; and the first nucleic acid strand is annealed to the second nucleic acid strand.

Abstract: CD4 mimic compounds having improved efficacy for anti-HIV treatment and more improved pharmacokinetics are provided. The compounds are represented by formula (I): wherein R1 is C2H4(OC2H4)n—OCH3 or CmH2m+1; R2 is O or NH; n is 3 to 25; and m is 4 to 22, or a salt thereof. HIV infection inhibitor compositions including the compound or a salt thereof as an active ingredient are also disclosed.

Abstract: A biometric information display apparatus (30) for displaying a measurement result obtained by measuring a biometric signal, includes a maximum value calculation unit (63) configured to calculate a maximum value of the measurement result in a certain period of time for at least one of blocks into which a measurement area, in which the biometric signal is measured, is divided, a determination unit (64) configured to determine whether a measurement value in the at least one of blocks is greater than or equal to a threshold value obtained by multiplying the maximum value by a fractional value, the fractional value being determined in advance, and a display control unit configured to display, in response to an occurrence of an event in which the measurement value is determined to be greater than or equal to the threshold value, the measurement result in such a manner as to indicate the occurrence of the event.

Abstract: A non-transitory computer-readable recording medium has stored therein an evaluating program for causing a computer to execute a process including: specifying a wall of an inspection target in two or more moving images being obtained by photographing two types of cross sections of the inspection target, the two types of cross sections being orthogonal to each other; evaluating photographing quality of each of a plurality of first divisional regions obtained by dividing a region corresponding to the wall specified in a first image related to a first cross section among the two or more moving images; and evaluating photographing quality of each of a plurality of second divisional regions obtained by dividing a region corresponding to the wall specified in a second image related to a second cross section among the two or more moving images, the second cross section being different from the first cross section.

Abstract: The object of the present invention is to provide a nucleic acid agent that is efficiently delivered to the nervous system, for example, the central nervous system to which drug delivery can be prevented by BBB, and produces an antisense effect on the target transcriptional product at the delivery site, and a composition comprising the same. In an embodiment, the present invention provides a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand that hybridizes to a part of a target transcriptional product and has an antisense effect on the target transcriptional product, and a second nucleic acid strand that comprises a base sequence complementary to the first nucleic acid strand and is bound to a C22-35 alkyl group optionally substituted with a hydroxy group or an analog thereof.